Bank of New York Mellon’s Stemline Therapeutics, Inc. STML Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q2 | – | Sell |
-184,334
| Closed | -$892K | – | 4201 |
|
|
2020
Q1 | $892K | Sell |
184,334
-746
| -0.4% | -$4.84K | ﹤0.01% | 3067 |
|
|
2019
Q4 | $1.97M | Buy |
185,080
+2,272
| +1% | +$22.6K | ﹤0.01% | 2826 |
|
|
2019
Q3 | $1.9M | Buy |
182,808
+20,760
| +13% | +$272K | ﹤0.01% | 2779 |
|
|
2019
Q2 | $2.48M | Sell |
162,048
-9,154
| -5% | -$132K | ﹤0.01% | 2686 |
|
|
2019
Q1 | $2.2M | Buy |
171,202
+36,446
| +27% | +$412K | ﹤0.01% | 2731 |
|
|
2018
Q4 | $1.28M | Buy |
134,756
+28,198
| +26% | +$366K | ﹤0.01% | 2968 |
|
|
2018
Q3 | $1.77M | Buy |
106,558
+2,752
| +3% | +$44.1K | ﹤0.01% | 2917 |
|
|
2018
Q2 | $1.67M | Sell |
103,806
-9,772
| -9% | -$174K | ﹤0.01% | 2963 |
|
|
2018
Q1 | $1.74M | Buy |
113,578
+12,765
| +13% | +$199K | ﹤0.01% | 2887 |
|
|
2017
Q4 | $1.57M | Buy |
100,813
+18,899
| +23% | +$253K | ﹤0.01% | 2986 |
|
|
2017
Q3 | $909K | Sell |
81,914
-4,282
| -5% | -$40.3K | ﹤0.01% | 3279 |
|
|
2017
Q2 | $794K | Sell |
86,196
-895
| -1% | -$7.46K | ﹤0.01% | 3383 |
|
|
2017
Q1 | $745K | Buy |
87,091
+23,077
| +36% | +$210K | ﹤0.01% | 3400 |
|
|
2016
Q4 | $685K | Buy |
64,014
+14,281
| +29% | +$173K | ﹤0.01% | 3448 |
|
|
2016
Q3 | $539K | Sell |
49,733
-2,375
| -5% | -$19.3K | ﹤0.01% | 3500 |
|
|
2016
Q2 | $353K | Sell |
52,108
-2,438
| -4% | -$15.4K | ﹤0.01% | 3682 |
|
|
2016
Q1 | $254K | Buy |
54,546
+315
| +0.6% | +$1.54K | ﹤0.01% | 3704 |
|
|
2015
Q4 | $343K | Sell |
54,231
-285
| -0.5% | -$2.31K | ﹤0.01% | 3674 |
|
|
2015
Q3 | $482K | Sell |
54,516
-19,904
| -27% | -$209K | ﹤0.01% | 3600 |
|
|
2015
Q2 | $876K | Sell |
74,420
-4,843
| -6% | -$67.2K | ﹤0.01% | 3411 |
|
|
2015
Q1 | $1.15M | Buy |
79,263
+24,662
| +45% | +$377K | ﹤0.01% | 3226 |
|
|
2014
Q4 | $932K | Buy |
54,601
+5,599
| +11% | +$80.7K | ﹤0.01% | 3347 |
|
|
2014
Q3 | $610K | Buy |
49,002
+170
| +0.3% | +$2.09K | ﹤0.01% | 3550 |
|
|
2014
Q2 | $717K | Buy |
48,832
+8,521
| +21% | +$131K | ﹤0.01% | 3484 |
|
|
2014
Q1 | $820K | Sell |
40,311
-758
| -2% | -$18.4K | ﹤0.01% | 3381 |
|
|
2013
Q4 | $805K | Sell |
41,069
-1,649
| -4% | -$44K | ﹤0.01% | 3405 |
|
|
2013
Q3 | $1.93M | Buy |
42,718
+7,232
| +20% | +$236K | ﹤0.01% | 2868 |
|
|
2013
Q2 | $846K | Buy |
+35,486
| New | +$565K | ﹤0.01% | 3276 |
|
Bank of New York Mellon's STML Position: Q2 2020 in Review
Bank of New York Mellon sold out of Stemline Therapeutics, Inc. (STML) in Q2 2020, closing a stake of 184,334 shares — an estimated $892K sold.
Bank of New York Mellon first reported a position in STML in Q2 2013 and held it in 28 quarters. The position peaked at $2.48M in Q2 2019. 0 funds tracked by Wall St. Rank hold STML as of Q2 2020.
- Bank of New York Mellon reported no remaining Stemline Therapeutics, Inc. position as of Q2 2020 after selling out during the quarter.
- Bank of New York Mellon sold 184,334 Stemline Therapeutics, Inc. shares in Q2 2020, an estimated $892K.
- Bank of New York Mellon first reported a position in Stemline Therapeutics, Inc. in Q2 2013 and held it in 28 quarters.
- Bank of New York Mellon's Stemline Therapeutics, Inc. position peaked at $2.48M in Q2 2019.
- 0 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2020.
Based on Bank of New York Mellon's 13F filing for Q2 2020, filed 12 Aug 2020.